

**BIOCON GROUP**

**FACT SHEET**

**June - 2021**

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			
(Rs. Crores)			
<b>Particulars</b>	<b>Q1'FY 22</b>	<b>Q1'FY 21</b>	<b>Variance %</b>
<b>INCOME</b>			
Generics	486	621	-22%
Biosimilars	758	692	10%
Novel Biologics	11	-	100%
Research services	595	422	41%
Inter-segment	(89)	(41)	119%
<b>Revenue from operations #</b>	<b>1,761</b>	<b>1,694</b>	<b>4%</b>
Other income	47	18	158%
<b>TOTAL REVENUE</b>	<b>1,808</b>	<b>1,712</b>	<b>6%</b>
<b>EXPENDITURE</b>			
Material & Power costs	686	624	10%
Staff costs	395	359	10%
Research & Development expenses*	120	107	12%
Other expenses	171	191	-11%
<b>Manufacturing, staff &amp; other expenses</b>	<b>1,371</b>	<b>1,281</b>	<b>7%</b>
<b>EBITDA</b>	<b>437</b>	<b>432</b>	<b>1%</b>
Interest & Finance charges	20	13	59%
Depreciation & Amortisation	195	167	17%
Share of loss / (profit) in JV / Associate, net	56	4	100%
<b>PBT</b>	<b>166</b>	<b>249</b>	<b>-33%</b>
Taxes	57	81	-29%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>108</b>	<b>168</b>	<b>-35%</b>
Minority interest	24	18	30%
<b>NET PROFIT FOR THE PERIOD</b>	<b>84</b>	<b>149</b>	<b>-44%</b>
<b>EPS Rs.</b>	<b>0.7</b>	<b>1.2</b>	
# Licensing Income	10	10	
* Gross Research & Development expenses	136	142	

<b>BIOCON LIMITED (CONSOLIDATED)</b>			(Rs. Crores)
<b>PROFIT &amp; LOSS STATEMENT</b>			
Particulars	Q1' FY 22	Q4' FY 21	Variance %
<b>INCOME</b>			
Generics	486	570	-15%
Biosimilars	758	664	14%
Novel Biologics	11	11	5%
Research services	595	659	-10%
Inter-segment	(89)	(61)	46%
<b>Revenue from operations #</b>	<b>1,761</b>	<b>1,842</b>	<b>-4%</b>
Other income	47	205	-77%
<b>TOTAL REVENUE</b>	<b>1,808</b>	<b>2,048</b>	<b>-12%</b>
<b>EXPENDITURE</b>			
Material & Power costs	686	647	6%
Staff costs	395	414	-5%
Research & Development expenses*	120	127	-6%
Other expenses	171	218	-22%
<b>Manufacturing, staff &amp; other expenses</b>	<b>1,371</b>	<b>1,406</b>	<b>-2%</b>
<b>EBITDA</b>	<b>437</b>	<b>641</b>	<b>-32%</b>
Interest & Finance charges	20	34	-41%
Depreciation & Amortisation	195	184	6%
Share of loss / (profit) in JV / Associate, net	56	70	100%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>166</b>	<b>353</b>	<b>-53%</b>
Exceptional item, Net	-	13	-
<b>PBT</b>	<b>166</b>	<b>366</b>	<b>-55%</b>
Taxes	57	60	-4%
Taxes on exceptional item	-	10	-
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>108</b>	<b>296</b>	<b>-63%</b>
Minority interest	24	36	-34%
Minority interest on exceptional item	-	7	-
<b>NET PROFIT FOR THE PERIOD</b>	<b>84</b>	<b>254</b>	<b>-67%</b>
<b>EPS Rs.</b>	<b>0.7</b>	<b>2.1</b>	
<b>NET PROFIT BEFORE EXCEPTIONAL ITEM</b>			
	84	257	-67%
Exceptional item, net of taxes	-	(4)	-
<b>NET PROFIT FOR THE PERIOD</b>	<b>84</b>	<b>254</b>	<b>-67%</b>
# Licensing Income	10	8	
* Gross Research & Development expenses	136	136	

**BIOCON LIMITED (CONSOLIDATED)**  
**BALANCE SHEET**

(Rs. Crores)

Particulars	June 30, 2021	March 31, 2021
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, plant and equipment	5,607	5,557
(b) Capital work-in-progress	2,452	2,254
(c) Right-of-use assets	160	153
(d) Goodwill	26	26
(e) Other intangible assets	643	627
(f) Intangible assets under development	566	547
(g) Investment in associates and a joint venture	128	180
(h) Financial assets		
Investments	386	564
Derivative assets	85	66
Other financial assets	130	201
(i) Income tax asset, net	266	265
(j) Deferred tax asset, net	302	308
(k) Other non-current assets	180	176
<b>Non-current assets</b>	<b>10,930</b>	<b>10,922</b>
<b>Current assets</b>		
(a) Inventories	2,156	1,867
(b) Financial assets		
Investments	1,436	1,209
Trade receivables	1,266	1,218
Cash and cash equivalents	900	953
Other bank balances	1,055	1,062
Derivative assets	64	83
Other financial assets	624	793
(c) Other current assets	388	364
(c) Assets held for sale	-	52
<b>Current assets</b>	<b>7,890</b>	<b>7,600</b>
<b>TOTAL - ASSETS</b>	<b>18,820</b>	<b>18,522</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity share capital	600	600
(b) Other equity	7,142	7,027
<b>Equity attributable to owners of the Company</b>	<b>7,742</b>	<b>7,627</b>
Non-controlling interests	903	881
<b>Total Equity</b>	<b>8,645</b>	<b>8,508</b>
<b>Non-current liabilities</b>		
(a) Financial liabilities		
Borrowings	2,901	2,962
Lease liabilities	115	114
Derivative liabilities	64	62
Other financial liabilities	1,503	1,503
(b) Provisions	109	106
(c) Deferred tax liability, net	34	32
(d) Other non-current liabilities	1,041	1,025
<b>Non-current liabilities</b>	<b>5,766</b>	<b>5,805</b>
<b>Current liabilities</b>		
(a) Financial liabilities		
Borrowings	596	594
Lease liabilities	17	8
Trade payables	1,637	1,514
Derivative liabilities	29	26
Other financial liabilities	1,318	1,184
(b) Provisions	119	109
(c) Income tax liability, net	146	152
(d) Other current liabilities	549	581
(e) Liabilities classified as held for sale	-	40
<b>Current liabilities</b>	<b>4,409</b>	<b>4,210</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>18,820</b>	<b>18,522</b>